Carlson Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Carlson Capital’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,000	Closed	-$864K	–	135
2023 Q3	$864K	Hold	25,000	–	–	0.07%	118
2023 Q2	$1.02M	Sell	25,000 -15,000	-38%	-$612K	0.09%	102
2023 Q1	$1.55M	Buy	40,000 +5,000	+14%	+$206K	0.15%	94
2022 Q4	$1.55M	Sell	35,000 -10,000	-22%	-$421K	0.12%	98
2022 Q3	$1.92M	Buy	45,000 +10,000	+29%	+$512K	0.14%	97
2022 Q2	$1.95M	Hold	35,000	–	–	0.13%	101
2022 Q1	$2.17M	Sell	35,000 -5,000	-13%	-$306K	0.15%	120
2021 Q4	$2.21M	Buy	+40,000	New	+$2.09M	0.13%	113

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Carlson Capital's LKFT Position: Q4 2023 in Review

Carlson Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2023, closing a stake of 25,000 shares — an estimated $864K sold.

Carlson Capital first reported a position in LKFT in Q4 2021 and held it in 8 quarters. The position peaked at $2.21M in Q4 2021. 88 funds tracked by Wall St. Rank hold LKFT as of Q4 2023.

Carlson Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2023 after selling out during the quarter.
Carlson Capital sold 25,000 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2023, an estimated $864K.
Carlson Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2021 and held it in 8 quarters.
Carlson Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.21M in Q4 2021.
88 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2023.

Based on Carlson Capital's 13F filing for Q4 2023, filed 13 Feb 2024.